Navigation Links
Study Links Agent Orange to Prostate Cancer in Vietnam Vets
Date:8/6/2008

But some researchers say the finding fails to establish cause-and-effect

WEDNESDAY, Aug. 6 (HealthDay News) -- Vietnam veterans exposed to the defoliant Agent Orange have a significantly greater risk of prostate cancer, especially the most aggressive form of the disease, a new study contends.

The findings are the first to connect the now-banned herbicide with this form of cancer, the researchers said.

"Veterans that were exposed to Agent Orange during the Vietnam War have a twofold higher risk of prostate cancer," said study lead author Dr. Karim Chamie, a resident physician in urology at the University of California, Davis, Department of Urology and the VA Northern California Health Care System. "The cancer they get tends to be more aggressive, a higher grade, and is more likely to spread or have spread at the time that they present to their urologist."

"A lot of veterans don't get their care through the VA [Veterans Administration]," Chamie added. "This message needs to go out to their physicians and their urologist in the private community to know that this is a large risk factor."

But some scientists not involved with the study said the research does not prove a cause-and-effect relationship between Agent Orange and prostate cancer.

For the study, Chamie's team collected data on 13,144 Vietnam veterans, including 6,214 men exposed to Agent Orange between 1962 and 1971.

The researchers found that twice as many veterans exposed to Agent Orange had developed prostate cancer, compared with veterans not exposed to the now-banned chemical.

Moreover, men exposed to Agent Orange were diagnosed with prostate cancer two-and-a-half years younger than unexposed men. And, they were four times more likely to be diagnosed with metastatic disease, the researchers found.

The findings were published online Monday in Cancer and were expected to be published in the Sept. 15 print issue of the journal.

Agent Orange is made up of compounds known to be contaminated with the dioxin tetrachlorodibenzo-para-dioxin (TCDD) during manufacture. The chemical was named for the color of the barrel it was stored in and was one of the "broad-leaf defoliants" used in Vietnam to destroy vegetation to make enemy activity easier to see.

Between 1962 and 1971, more than 20 million gallons of Agent Orange were sprayed during the war, contaminating both the ground and soldiers. The International Agency for Research on Cancer reclassified TCDD a group 1 carcinogen in 1997, a classification that also includes arsenic, asbestos and gamma radiation, according to background information with the study.

Dr. Bruce Roth, a professor of medicine and urologic surgery at Vanderbilt University, said he found the study interesting but not persuasive.

"I'm not totally convinced," Roth said, noting that the study relies on self-reported exposure to Agent Orange, without other objective proof of exposure or the amount of exposure.

Roth speculated that because all study participants who reported being exposed to Agent Orange were given thorough screening tests for prostate cancer, more cancers were found. "I can almost guarantee you're going to find more cases of prostate cancer," he said.

"I'm not saying that there is not possibly some relationship, but I don't think that this paper necessarily proves it," Roth said. "But I think you could pick almost any exposure and increase screening, and you are going to find more cases, whether or not the agent is responsible for more cases or not."

Dr. Michael J. Thun, vice president of epidemiology and surveillance research at the American Cancer Society, agreed that the findings were interesting but don't prove a connection between prostate cancer and Agent Orange.

"The finding is provocative, but it's hard to know how to interpret it, unless it can be replicated in other studies," Thun said.

More information

For more on prostate cancer, visit the American Cancer Society .



SOURCES: Karim Chamie, M.D., resident physician in urology, VA Northern California Health Care System; Bruce Roth, M.D., professor, medicine and urologic surgery, Vanderbilt University, Nashville, Tenn.; Michael J. Thun, M.D., vice president of epidemiology and surveillance research, American Cancer Society, Atlanta; Sept. 15, 2008, Cancer, early online release


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... Las Vegas, Nevada (PRWEB) , ... June 24, ... ... their Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and ... The Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: